Do sporting events amplify airborne virus transmission? Causal evidence from US professional team sports

We analyze the impact of professional sporting events on local seasonal influenza mortality to develop evidence on the role played by spectator attendance at sporting events in airborne virus transmission. Results from a difference-in-differences model applied to data from a sample of US cities that gained new professional sports teams over the period 1962–2016 show that the presence of games in these cities increased local influenza mortality by between 4% and 24%, depending on the sport, relative to cities with no professional sports teams and relative to mortality in those cities before a new team arrived. Influenza mortality fell in cities with teams in some years when work stoppages occurred in sports leagues. Health policy decisions, and decisions about the subsidization of professional sports, should take into account the role played by sporting events in increasing airborne virus transmission and local influenza and coronavirus mortality.

Influenza-associated mortality in Australia, 2010 through 2019: High modelled estimates in 2017.

INTRODUCTION: In Australia, the 2017 and 2019 influenza seasons were severe. High-dose or adjuvanted vaccines were introduced for ≥65 year-olds in 2018. AIM: To compare influenza-associated mortality in 2017 and 2019 with the average for 2010-2019. METHODS: We used time series modelling to obtain estimates of influenza-associated death rates for influenza A(H1N1)pdm09, A(H3N2) and B in Australia, in persons of all ages and <65, 65-74 and ≥75 years. Estimates were made for pneumonia and influenza (P&I, 2010-2018), respiratory (2010-2018), and all-cause outcomes (2010-2019). RESULTS: During 2010 through 2018 (and 2019 for all-cause), influenza was estimated to be associated with an annual average of 2.1 (95% confidence interval (CI) 1.9, 2.4), 4.0 (95% CI 3.4, 4.6), and 11.6 (95% CI 8.4, 15.0) P&I, respiratory and all-cause deaths per 100,000 population, respectively. Influenza A(H1N1)pdm09 was estimated to be associated with less than one quarter of influenza-associated P&I and respiratory deaths, while A(H3N2) and B were each estimated to contribute approximately equally to the remaining influenza-associated deaths. In 2017, the respective rates were 7.8 (95% CI 7.1, 8.4), 12.3 (95% CI 10.9, 13.6) and 26.0 (95% CI 20.8, 32.0) per 100,000. In 2019, the all-cause estimate was 20.8 (95% CI 14.9, 26.7) per 100,000. CONCLUSIONS: Seasonal influenza continues to be associated with substantial mortality in Australia, with at least double the average occurring in 2017. Age-specific monitoring of vaccine effectiveness is needed in Australia to understand higher mortality seasons.

Tail risks and infectious disease: Influenza mortality in the U.S., 1900-2018.

I use extreme values theory and data on influenza mortality from the U.S. for 1900 to 2018 to estimate the tail risks of mortality. I find that the distribution for influenza mortality rates is heavy-tailed, which suggests that the tails of the mortality distribution are more informative than the events of high frequency (i.e., years of low mortality). I also discuss the implications of my estimates for risk management and pandemic planning.